跳到正文
验证登录状态…
原文
BioSpace · Funding·· 17 天前精选AI 评分60

Astrocyte Pharmaceuticals完成950万美元B轮融资,推进AST-004二期临床

Astrocyte Pharmaceuticals Secures $9.5 Million Series B to Advance Phase 2 Clinical Development of Breakthrough TBI and Concussion Therapy AST-004

AI 导读

Astrocyte Pharmaceuticals宣布完成950万美元B轮融资,由DeepWork Capital领投,现有投资者继续支持,MintPharma Capital、Waterstar Capital、Dynagrow Capital和Angel Star Ventures参与。 公司:Astrocyte Pharmaceuticals 相关资产:AST-004 适应症:脑震荡、创伤性脑损伤、急性缺血性卒中 阶段:Phase 2 融资性质:股权 来源:BioSpace · Funding(https://www.biospace.com/press-releases/astrocyte-pharmaceuticals-secures-9-5-million-series-b-to-advance-phase-2-clinical-development-of-breakthrough-tbi-and-concussion-therapy-ast-004)

推荐理由

了解脑损伤领域临床阶段公司B轮融资规模、投资方及AST-004二期读出时点。

来源:BioSpace · Funding · biospace.com

正在验证登录状态…